year: 2019
pmid: '30659283'
Path: /mechanisms/senescence-therapeutic-targeting
Cellular senescence represents a fundamental aging mechanism that contributes to neurodegeneration through both cell-intrinsic dysfunction and the senescence-associated secretory phenotype (SASP)[1]. As senescent cells accumulate in the aging brain, they create a chronic pro-inflammatory microenvironment that drives pathology in Alzheimer's disease, Parkinson's disease, and related disorders[2]. Therapeutic targeting of senescence offers two complementary strategies: senolytic drugs that eliminate senescent cells, and senomorphic agents that suppress the harmful SASP without cell death[3].
This page provides a comprehensive overview of therapeutic approaches to target cellular senescence in neurodegenerative diseases, including mechanistic details, clinical trial status, and intervention points for drug development.
Senolytic drugs selectively induce apoptosis in senescent cells while sparing normal cells. The selective toxicity derives from the heightened dependence of senescent cells on anti-apoptotic pathways—particularly the Bcl-2 family proteins—to survive their pro-inflammatory state[4].
The combination of dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) represents the most extensively studied senolytic regimen[1:1]. This combination was identified through high-throughput screening and demonstrated broad senolytic activity across multiple tissue types[5].
Dasatinib is an FDA-approved drug for chronic myeloid leukemia that inhibits multiple kinases including Bcr-Abl and Src family kinases. In senescent cells, dasatinib targets Bcl-2, Bcl-xL, and Bcl-w survival proteins, shifting the balance toward apoptosis[4:1].
Quercetin is a natural flavonoid with multiple senolytic mechanisms including PI3K/Akt inhibition, Bcl-2 family modulation, and direct effects on multiple pro-survival pathways[6]. The combination achieves synergistic senolytic activity with lower doses of each compound than would be required alone.
The D+Q combination has demonstrated preclinical efficacy in neurodegenerative disease models. In tauopathy mice, senolytic treatment reduced senescent glial cells and prevented tau-dependent pathology progression[7]. In Alzheimer's disease models, D+Q reduced cognitive decline and neuroinflammation through clearance of senescent microglia[8].
Navitoclax is a Bcl-2 family inhibitor that targets Bcl-2, Bcl-xL, and Bcl-w[5:1]. Originally developed as an anti-cancer agent, navitoclax demonstrated potent senolytic activity particularly against senescent fibroblasts and astrocytes.
The mechanism involves:
Navitoclax has shown particular efficacy against senescent microglia and neurons in vitro, making it relevant for neurodegenerative applications[9].
| Agent | Primary Target | Status | CNS Penetration |
|---|---|---|---|
| ABT-737 | Bcl-2, Bcl-xL, Bcl-w | Preclinical | Limited |
| Fisetin | Multiple | Preclinical | Moderate |
| Piperlongumine | ROS pathways | Preclinical | Unknown |
| 17-DMAG | Hsp90 | Preclinical | Limited |
Senomorphic drugs do not eliminate senescent cells but instead suppress the production and secretion of SASP factors[3:1]. This approach may offer advantages when complete senescent cell removal could have unintended consequences, such as impairing wound healing or tissue repair[10].
The mechanistic target of rapamycin (mTOR) pathway serves as a central regulator of SASP production[11]. Rapamycin inhibits mTORC1, which:
Rapamycin maintains the senescent cell growth arrest while rendering cells metabolically "quiet" with reduced SASP secretion[14]. This dual action—SASP suppression plus autophagy induction—makes rapamycin particularly potent.
Metformin, the widely prescribed type 2 diabetes medication, exhibits senostatic properties through AMPK activation and subsequent mTOR inhibition[15]. Metformin:
Large observational studies suggest reduced dementia risk in diabetic patients treated with metformin, and clinical trials are evaluating metformin's neuroprotective effects in non-diabetic patients.
The JAK-STAT pathway plays a critical role in SASP maintenance and autocrine signaling[16]. JAK inhibitors including ruxolitinib and tofacitinib:
In preclinical models, JAK inhibition reduced SASP-induced cognitive decline and neuroinflammation.
Beyond direct senolytic and senomorphic approaches, additional strategies target specific aspects of SASP biology:
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) serves as the master regulator of SASP transcription. Inhibitors targeting this pathway include:
p38 mitogen-activated protein kinase contributes to SASP regulation through transcription factor C/EBPβ phosphorylation and SASP mRNA stabilization:
The NLRP3 inflammasome represents a key SASP-related target:
| Trial ID | Agent | Phase | Condition | Status |
|---|---|---|---|---|
| NCT02848131 | D+Q | I | COPD/aging | Completed |
| NCT03415087 | D+Q | I | Alzheimer's | Completed |
| NCT04685590 | D+Q | I/II | Parkinson's | Recruiting |
| NCT04833517 | D+Q | II | Cognitive decline | Planning |
The first human senolytic trial (NCT02848131) in idiopathic pulmonary fibrosis demonstrated reduced senescent cell burden in peripheral blood with D+Q treatment[17]. A Phase I trial in Alzheimer's disease (NCT03415087) established safety and showed biomarker signals consistent with reduced senescence burden.
Key challenges for clinical translation include:
The senescence-associated secretory phenotype (SASP) includes numerous secreted factors that can serve as biomarkers[18]:
| Biomarker | Source | Utility |
|---|---|---|
| IL-6 | Serum | Highest correlation with senescence |
| IL-8 | Serum | SASP marker |
| PAI-1 | Plasma | Senescence-specific |
| CXCL1 | Serum | Pro-inflammatory |
| VEGF | Plasma | Angiogenic SASP |
SA-β-Gal staining: Classic histochemical marker; limited to tissue samples
p16 and p21 markers:
DNA damage markers:
Emerging approaches:
Cellular senescence in AD primarily affects[19]:
Therapeutic approach: Senolytic clearance of senescent glia followed by senomorphic treatment to prevent re-accumulation
Senescence in PD involves:
Special considerations: The substantia nigra has high baseline oxidative stress, making combination approaches (antioxidants + senolytics) attractive
In ALS, senescence affects:
FTD shows senescence in:
| Drug/Compound | Target | Stage | Notes |
|---|---|---|---|
| Dasatinib + Quercetin | Bcl-2, PI3K | Phase 1-2 | Most advanced |
| Navitoclax (ABT-263) | Bcl-2/xL/w | Preclinical | Thrombocytopenia |
| Fisetin | Multiple | Preclinical | Natural product |
| ABT-737 | Bcl-2/xL/w | Preclinical | Limited solubility |
| Piperlongumine | ROS pathways | Preclinical | Unclear mechanism |
| 17-DMAG | Hsp90 | Preclinical | Limited CNS penetration |
| Drug/Compound | Target | Stage | Notes |
|---|---|---|---|
| Rapamycin | mTOR | Approved (other) | Neuroprotective |
| Metformin | AMPK/mTOR | Approved (DM) | Safety established |
| Ruxolitinib | JAK1/2 | Approved (RA) | Immunosuppression |
| MCC950 | NLRP3 | Preclinical | Potent inflammasome inhibitor |
Senolytic antibodies: Targeting senescent cell surface antigens (uPAR, CD9) for antibody-dependent cellular cytotoxicity
Galactoside-based prodrugs: Activated specifically in senescent cells by elevated β-galactosidase
Gene therapy: Targeted expression of pro-apoptotic genes in senescent cells
Combining senolytic and senostatic approaches may provide synergistic benefits[1:2]:
Targeting multiple hallmarks of aging:
Rationale: Neurodegeneration involves multiple interconnected pathways; monotherapy may be insufficient
Off-target effects: Senolytic drugs may affect non-senescent cells, particularly during repeated dosing
Wound healing impairment: Senescent cells play important roles in tissue repair[10:1]
Immune modulation: Chronic senolytic treatment may affect immune surveillance
Thrombocytopenia: Bcl-2 family inhibitors can cause platelet depletion
Monbut invasive |
The senescence-associated secretory phenotype provides accessible biomarkers:
Single-cell approaches reveal cell-type-specific senescence signatures:
Senolytics face unique regulatory challenges:
| Agent | Status | Indication |
|---|---|---|
| Dasatinib | FDA-approved | CML (leukemia) |
| Quercetin | Available as supplement | N/A (not approved) |
| Rapamycin | FDA-approved | Transplant, rare diseases |
| Metformin | FDA-approved | Type 2 diabetes |
Repurposing existing drugs for senolytic indications offers faster development paths.
Future therapies will likely combine:
Understanding cell-type-specific senescenalth and disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28593998/)
6. van Deursen, The role of senescent cells in ageing (2014)
7. Zhu et al., Senolytic combinations for maximum effect (2016)
8. Laberge et al., MTOR regulates the pro-tumorigenic SASP (2015)
9. Moiseeva et al., Metformin suppresses the SASP (2013)
10. Xu et al., JAK inhibition alleviates the SASP (2015)
11. Trias et al., Senolytics eliminate senescent glia (2019)
12. Hickson et al., Senolytics decrease senescent cells in humans (2023)
13. Chaib et al., Cellular senescence and senolytics: the path to translating age-related interventions (2022)
14. Seluanov et al., Cellular senescence and the SASP in age-related diseases (2021)
15. Ogrodnik et al., Cellular senescence drives age-related dysfunction in neurodegenerative diseases (2021)
16. Justice et al., Senolytics: pharmacological interventions for aging (2024)
17. Demaria et al., An essential role for senescent cells in optimal wound healing (2014)
18. Baker & Petersen, Cellular senescence in brain aging and neurodegenerative diseases (2018)
19. Coppé et al., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions (2008)
20. Blagosklonny, Rapamycin treatment of human cells (2013)
Kirkland JL, Tchkonia T. "Clinical strategies for targeting senescent cells". Nat Rev Drug Discov. 2018. ↩︎ ↩︎ ↩︎
Baker DJ, Petersen RC. "Cellular senescence in brain aging and neurodegenerative diseases". Lancet Neurol. 2018. ↩︎
He S, Sharpless NE. "Senescence in health and disease". Cell. 2017. ↩︎ ↩︎
Xu M, Pirtskhalava T, Farr JN, et al. "Senolytics improve physical function and increase lifespan in old age". Nat Med. 2018. ↩︎ ↩︎
Zhu Y, et al. "Senolytic combinations for maximum effect". Aging Cell. 2016. ↩︎ ↩︎
Chaib S, Tchkonia T, Kirkland JL. "Cellular senescence and senolytics: the path to translating age-related interventions". Nat Rev Drug Discov. 2022. ↩︎
Bussian TJ, Aziz A, Meyer CF, et al. "Clearance of senescent glial cells prevents tau-dependent pathology". Nature. 2018. ↩︎
Musi N, Valentine JM, Sickora KR, et al. "Tau protein aggregation is associated with cellular senescence in the brain". Aging Cell. 2018. ↩︎
Trias E, et al. "Senolytics eliminate senescent glia". Nat Neurosci. 2019. ↩︎
Demaria M, et al. "An essential role for senescent cells in optimal wound healing". Dev Cell. 2014. ↩︎ ↩︎
Laberge RM, et al. "MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype". Nat Cell Biol. 2015. ↩︎
Herranz N, et al. "mTOR regulates MAPKAP-K2 activity to regulate the cellular senescence-associated secretory phenotype". Nat Cell Biol. 2015. ↩︎
Wang R, et al. "mTOR and NLRP3 inflammasome activation in senescence". Aging Cell. 2019. ↩︎
Blagosklonny MV. "Rapamycin treatment of human cells". Cell Cycle. 2013. ↩︎
Moiseeva O, et al. "Metformin suppresses the senescence-associated secretory phenotype". Aging Cell. 2013. ↩︎
Xu M, et al. "JAK inhibition alleviates the cellular senescence-associated secretory phenotype". Aging Cell. 2015. ↩︎
Hickson LJ, Langhi Prata LGP, Bobart SA, et al. "Senolytics decrease senescent cells in humans: a pilot study". Aging Cell. 2023. ↩︎
Coppé JP, et al. "Senescence-associated secretory phenotypes reveal cell-nonautonomous functions". PLoS Biol. 2008. ↩︎
Ogrodnik M, et al. "Cellular senescence drives age-related dysfunction in neurodegenerative diseases". Trends Neurosci. 2021. ↩︎